Outcomes of TP53-mutated AML with evolving frontline therapies: Impact of allogeneic stem cell transplantation on survival

AMERICAN JOURNAL OF HEMATOLOGY

WILEY

1. Mayo Clinic Cancer Center [P30 CA015083]
2. Celularity
3. ADC Therapeutics
4. Aprea
5. AROG
6. Pfizer
7. Prelude
8. Trillium
9. Aptose
10. Daiichi Sankyo
11. AbbVie
12. Celgene/BMS
13. Agios/Servier